- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03505216
Swiss Paediatric Airway Cohort (SPAC)
The Swiss Paediatric Airway Cohort (SPAC) is a national, prospective clinical cohort of children and adolescents who visit physicians in Switzerland for recurrent wheeze, cough, and exercise- or sleep-related respiratory problems. SPAC aims to answer important questions on clinical phenotypes, prognosis, diagnosis and treatment. SPAC is part of routine care, and only clinically indicated investigations are done. The comprehensive baseline assessment includes a detailed questionnaire to families, plus test results, diagnoses and treatments from hospital records. Follow-up is via monthly questionnaires the first 12 months and thereafter annual questionnaires to families, and data from follow-up visits.
Currently, 4344 patients from 10 clinics and hospitals in Switzerland (Aarau, Basel, Bern, Chur, Horgen, Lausanne, Luzern, St. Gallen, Worb, Zurich) have been enrolled.
SPAC provides real-life data on children visiting the Swiss health care system for common respiratory problems. It will provide a research platform for health services research, and for nested clinical and transitional studies.
Publications and plain language summaries are listed on the study website: https://www.spac-study.ch/publikationen/
Study Overview
Status
Detailed Description
Background:
Many studies have investigated the epidemiology of asthma in childhood, but most were based on data from the general population gathered either in cross-sectional or longitudinal surveys in schoolchildren.
Objectives:
The Swiss Paediatric Airway Cohort (SPAC) was set up in 2017 as a large, longitudinal database that is representative of children and adolescents visiting physicians in Switzerland for recurrent wheeze, cough, and exercise- or sleep-related respiratory symptoms. It will constitute a national research platform for studying healthcare provision, phenotypes and prognosis of these problems, and a sampling frame for conducting nested studies.
Methods:
Recruitment and participation:
The SPAC study recruits patients aged 0-16 that are referred to a paediatric outpatient clinic for recurrent respiratory symptoms. Families receive a SPAC information package containing an invitation letter, study information leaflet, informed consent form, and questionnaire. Physicians introduce the study to them, answer questions, and collect informed consent forms. Completed questionnaires are brought by families to the clinics or sent directly by families to the SPAC study centre using a prepaid return envelope. Eligible patients have consultations in participating clinics regardless of their study participation. No tests are performed specifically for SPAC; examinations and tests are done only if clinically indicated or ordered by the referring physician. Examinations such as lung function, allergy, blood, or bronchial challenge tests are done using respective standard procedures in the clinics. SPAC research team members visit participating centres at regular intervals to collect data. During the first year, caregivers or patients who are 14 years or older receive short online questionnaire through a link via email. One year after enrolment and each year thereafter, caregivers receive a follow-up questionnaire by post.
Information collected:
Questionnaires:
At baseline families complete a detailed questionnaire that includes sections on frequency, duration, severity, triggers, and history of upper and lower respiratory symptoms, and diagnoses, treatments, health behaviours, environmental factors, family history, and contact information. The monthly online questionnaires focus on symptoms, infections, and treatments which may change short-term. The yearly follow-up questionnaires focus on symptoms, treatments, and important risk factors during the past 12 months. Postal addresses for mailing are obtained from hospital records and updated by contacting community registration offices, a procedure used successfully for other registries and cohort studies in Switzerland. Questionnaires are currently available in German and French.
Medical records:
Information obtained from medical records includes reasons for referral; anthropometric measures; results from the physical examination and diagnostic tests including pulmonary function, allergy, and blood tests; information about asthma control; and final diagnoses and prescribed treatments.
Linkage to routine data:
For specific analyses, probabilistic record linkage will be used to merge data from SPAC with routine datasets collected by the Swiss Federal Statistical Office.
Study database:
The SPAC database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.
Current status of the project:
SPAC recruits participants from 10 clinics in Switzerland including the children's hospital in Aarau, the University Children's hospital in Basel, the University Children's Hospital in Bern, the Children's hospital in Chur, a private paediatric pulmonology clinic in Horgen, the University Children's hospital in Lausanne, the Children's hospital in Luzern, the Children's hospital in St. Gallen, a private paediatric pulmonology clinic in Worb, and the University Children's Hospital in Zurich. By October 2023, 4344 children have agreed to participate in SPAC.
Publications and plain language summaries are listed on the study website: https://www.spac-study.ch/publikationen/
Funding:
Setting up SPAC was funded by the Swiss National Science Foundation (SNF32003B_162820, SNF320030_182628, SNF320030_212519), and several local funding bodies including the Swiss Lung Association, the Lung League of St. Gallen, and the Allergiestiftung Ulrich Müller-Gierok.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Claudia E Kuehni, Prof.
- Phone Number: +41(0)316843507
- Email: claudia.kuehni@unibe.ch
Study Locations
-
-
-
Vienna, Austria
- Recruiting
- Vienna Open Medical Institute
-
Contact:
- Clemens Maedel
-
Principal Investigator:
- Thomas Frischer
-
Sub-Investigator:
- Clemens Maedel
-
-
-
-
-
Aarau, Switzerland
- Recruiting
- Children's hospital Aarau
-
Contact:
- Dominik Müller-Suter
-
Principal Investigator:
- Dominik Müller-Suter
-
Sub-Investigator:
- Anja Jochmann
-
Basel, Switzerland
- Recruiting
- University Children's Hospital Basel, UKBB
-
Contact:
- Anja Jochmann
-
Principal Investigator:
- Anja Jochmann
-
Bern, Switzerland
- Recruiting
- University Children's Hospital Bern, Inselspital
-
Contact:
- Philipp Latzin
-
Principal Investigator:
- Philipp Latzin
-
Sub-Investigator:
- Florian Singer
-
Bern, Switzerland, 3012
- Recruiting
- Institute of Social and Preventive Medicine
-
Contact:
- Claudia E Kuehni, Prof
-
Principal Investigator:
- Claudia E Kuehni, Prof
-
Chur, Switzerland
- Recruiting
- Children's Hospital Chur
-
Contact:
- Carmen Casaulta
-
Principal Investigator:
- Carmen Casaulta
-
Sub-Investigator:
- Peter Iseli
-
Horgen, Switzerland
- Recruiting
- Pulmonology clinic, Horgen
-
Contact:
- Karin Hoyler
-
Principal Investigator:
- Karin Hoyler
-
Lausanne, Switzerland
- Not yet recruiting
- University Children's hospital Lausane, CHUV
-
Contact:
- Sylvain Blanchon
-
Principal Investigator:
- Sylvain Blanchon
-
Sub-Investigator:
- Isabelle Rochat
-
Lucerne, Switzerland
- Recruiting
- Children's hospital Lucerne
-
Contact:
- Nicolas Regamey
-
Principal Investigator:
- Nicolas Regamey
-
St. Gallen, Switzerland
- Recruiting
- Children's hospital St. Gallen
-
Contact:
- Juerg Barben
-
Principal Investigator:
- Juerg Barben
-
Worb, Switzerland
- Recruiting
- Pulmonology clinic, Worb
-
Contact:
- Claudia Kuehni
-
Principal Investigator:
- Claudia Kuehni
-
Zurich, Switzerland
- Recruiting
- University Children's Hospital Zurich
-
Contact:
- Alexander Moeller
-
Principal Investigator:
- Alexander Moeller
-
Sub-Investigator:
- Jakob Usemann
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children and adolescents aged 0-16 years
- Resident in Switzerland
- Seen in a paediatric pulmonary outpatient clinic due to respiratory problems
- Parents and patients above age 14 must be able to sign an informed consent form
Exclusion Criteria:
Prior diagnosis of cystic fibrosis, primary ciliary dyskinesia, severe heart disease, oncological disease, neuromuscular disease or severe disability
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Patient population
Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wheeze
Time Frame: 1 year from inclusion in SPAC study
|
Number of patients with current wheeze as measured with questionnaire
|
1 year from inclusion in SPAC study
|
Cough apart from colds
Time Frame: 1 year from inclusion in SPAC study
|
Number of patients with cough apart from colds as measured with questionnaires
|
1 year from inclusion in SPAC study
|
Exercise-induced dyspnea
Time Frame: 1 year from inclusion in SPAC study
|
Number of patients with exercise-induced dyspnea as measured with questionnaires
|
1 year from inclusion in SPAC study
|
Reduced lung function
Time Frame: 1 year from inclusion in SPAC study
|
Number of patients with reduced lung function measured through clinical tests in the paediatric pulmonary clinics (Spirometry, Fraction of Exhaled Nitric Oxide, Bronchial challenge test, Exercise challenge test).
Information collected through hospital records.
|
1 year from inclusion in SPAC study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wheeze
Time Frame: 5 years from inclusion in SPAC study
|
Number of patients with current wheeze as measured with questionnaire
|
5 years from inclusion in SPAC study
|
Cough apart from colds
Time Frame: 5 years from inclusion in SPAC study
|
Number of patients with Cough apart from colds as measured with questionnaire
|
5 years from inclusion in SPAC study
|
Exercise-induced dyspnea
Time Frame: 5 years from inclusion in SPAC study
|
Number of patients with Exercise-induced dyspnea as measured with questionnaire
|
5 years from inclusion in SPAC study
|
Reduced lung function
Time Frame: 5 years from inclusion in SPAC study
|
Number of patients with reduced lung function measured through clinical tests in the paediatric pulmonary clinics (Spirometry, Fraction of Exhaled Nitric Oxide,
|
5 years from inclusion in SPAC study
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Claudia E Kuehni, Prof., Institute of Social and Preventive Medicine
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Researchers who wish to develop a nested study with inclusion of additional data also need to submit a proposal to the SPAC committee and request permission. A concept sheet describing the planned analyses must be approved by the SPAC committee. If any additional data are collected by nested studies, these must be contributed to the SPAC database after the data collection. Nested studies might need separate ethics permission.
At the study website: www.spac-study.ch, information can be found on how to request permission to use data from the SPAC study.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
The First Affiliated Hospital of Zhejiang Chinese...Completed
-
ILiAD BiotechnologiesCompletedPertussis/Whooping Cough | Bordetella Pertussis, Whooping CoughUnited Kingdom
-
KK Women's and Children's HospitalSingapore University of Technology and DesignUnknownCough | URTI | Cough Variant Asthma | Cough; Bronchial, With Grippe or InfluenzaSingapore
-
Shanghai Zhongshan HospitalNot yet recruitingSufentanil-induced Cough
-
Merck Sharp & Dohme LLCCompletedChronic CoughCanada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
-
Khon Kaen UniversityCompleted
-
PhytoHealth CorporationCompleted